Robeco Institutional Asset Management B.V. boosted its position in Quest Diagnostics Inc. (NYSE:DGX) by 193.0% during the third quarter, Holdings Channel reports. The firm owned 181,372 shares of the company’s stock after buying an additional 119,461 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Quest Diagnostics were worth $15,350,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of DGX. Financial Architects Inc raised its position in shares of Quest Diagnostics by 6.4% in the second quarter. Financial Architects Inc now owns 1,476 shares of the company’s stock worth $120,000 after buying an additional 89 shares during the period. Pinkerton Retirement Specialists LLC raised its position in shares of Quest Diagnostics by 792.4% in the second quarter. Pinkerton Retirement Specialists LLC now owns 1,651 shares of the company’s stock worth $134,000 after buying an additional 1,466 shares during the period. Integrated Investment Consultants LLC raised its position in shares of Quest Diagnostics by 10.4% in the second quarter. Integrated Investment Consultants LLC now owns 1,869 shares of the company’s stock worth $152,000 after buying an additional 176 shares during the period. Creative Planning raised its position in shares of Quest Diagnostics by 13.5% in the second quarter. Creative Planning now owns 1,972 shares of the company’s stock worth $161,000 after buying an additional 234 shares during the period. Finally, Mizuho Asset Management Co. Ltd. raised its position in shares of Quest Diagnostics by 94.6% in the second quarter. Mizuho Asset Management Co. Ltd. now owns 2,020 shares of the company’s stock worth $164,000 after buying an additional 982 shares during the period. Institutional investors own 86.81% of the company’s stock.

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Shares of Quest Diagnostics Inc. (NYSE:DGX) traded down 0.411% on Wednesday, hitting $88.385. The stock had a trading volume of 292,293 shares. The company’s 50 day moving average is $83.51 and its 200 day moving average is $82.31. Quest Diagnostics Inc. has a one year low of $59.66 and a one year high of $89.16. The stock has a market cap of $12.25 billion, a PE ratio of 18.757 and a beta of 0.62.

Quest Diagnostics (NYSE:DGX) last announced its earnings results on Thursday, October 20th. The company reported $1.37 EPS for the quarter, beating analysts’ consensus estimates of $1.35 by $0.02. Quest Diagnostics had a net margin of 9.01% and a return on equity of 14.57%. The business earned $1.89 billion during the quarter, compared to analysts’ expectations of $1.53 billion. During the same period in the prior year, the company earned $1.28 earnings per share. The business’s revenue was up .3% compared to the same quarter last year. Equities research analysts predict that Quest Diagnostics Inc. will post $5.10 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, January 25th. Stockholders of record on Tuesday, January 10th will be issued a $0.45 dividend. This represents a $1.80 dividend on an annualized basis and a dividend yield of 2.03%. This is a boost from Quest Diagnostics’s previous quarterly dividend of $0.40. Quest Diagnostics’s dividend payout ratio is presently 34.04%.

TRADEMARK VIOLATION NOTICE: “Robeco Institutional Asset Management B.V. Boosts Position in Quest Diagnostics Inc. (DGX)” was originally posted by Financial Market News and is owned by of Financial Market News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this article can be read at http://www.financial-market-news.com/robeco-institutional-asset-management-b-v-boosts-position-in-quest-diagnostics-inc-dgx/1210760/.

A number of research firms have weighed in on DGX. Mizuho reiterated a “neutral” rating and set a $88.00 price objective on shares of Quest Diagnostics in a research note on Wednesday. Canaccord Genuity set a $90.00 price objective on Quest Diagnostics and gave the company a “buy” rating in a research note on Thursday, October 20th. Barclays PLC set a $85.00 price objective on Quest Diagnostics and gave the company a “hold” rating in a research note on Monday, November 14th. Bank of America Corp. reiterated a “sell” rating and set a $78.00 price objective on shares of Quest Diagnostics in a research note on Monday, November 14th. Finally, Zacks Investment Research upgraded Quest Diagnostics from a “hold” rating to a “buy” rating and set a $93.00 price objective for the company in a research note on Wednesday, September 21st. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and two have issued a buy rating to the stock. Quest Diagnostics currently has a consensus rating of “Hold” and a consensus target price of $83.14.

About Quest Diagnostics

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Company’s Diagnostic Information Services business develops and delivers diagnostic testing information and services to patients, physicians, health plans, hospitals, accountable care organizations (ACOs), integrated delivery networks (IDNs), other commercial laboratories, employers and others.

5 Day Chart for NYSE:DGX

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Inc. (NYSE:DGX).

Receive News & Ratings for Quest Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.